• 20 OCT 16

    Cancer deaths to cost Ireland €73 billion over the next 20 years

    Researchers at the National Cancer Registry Ireland found that deaths from cancer will result in lost productivity valued at €73 billion; €13 billion in lost paid work and €60 billion in lost unpaid activities. When people die from cancer, society loses their contribution to the economy through paid work and unpaid activities such as housework, caring for relatives and volunteering. This work provides a complementary perspective on the burden of cancer in Ireland, and can be used to inform policy makers and health services about priorities for cancer care and research in the future.

    Read more →
    • 18 OCT 16

    HSRAANZ Annual General Meeting and Symposium – Health Services Research – where to from here? A review of the state and potential of HSR in Australia and New Zealand

    Registrations are now open for the Association’s Annual General Meeting and Symposium – Health Services Research – where to from here? on 1 December 2016 at the National Press Club, Canberra. At the event we will launch the preliminary findings of a commissioned report on the state and potential of HSR in Australia and New Zealand. This will be accompanied by short presentations by leading health services researchers describing the impact of their HSR on the Australian and New Zealand healthcare system and population health. Following the report launch and presentations, we will be holding break-out sessions to discuss the potential role and approaches to HSR in Australia and New Zealand in different sectors of the healthcare system (e.g. public hospitals, primary care, aged care, public health).

    Read more →
    • 18 OCT 16

    HSRAANZ Members – tell us about your research

    We want to encourage and help HSRAANZ members to publicise their research. You can do this simply, by completing our template. All we require is a 500 word summary for the HSRAANZ Blog, a 100 word summary for the HSRAANZ email newsletter and a 140 character summary for @hsraanz so that we can tweet about the paper and share a link to the blog. You can also post a photo of yourself or your team. For an example of how this can be done take a look at the post below “When newer isn’t better: We’re paying too much for patented pharmaceuticals” which looks at the latest research from our President, Jon Karnon

    Read more →
    • 18 OCT 16

    When newer isn’t better: We’re paying too much for patented pharmaceuticals.

    New pharmaceuticals are often listed on the Pharmaceutical Benefits Schedule at the same price as an equivalent pharmaceutical. Analysis of denosumab for the treatment of osteoporosis shows that the government has been paying almost $250,000 to gain the equivalent of one additional quality adjusted life year (QALY) since its comparator, alendronate went off patent. The Australian government should review listed pharmaceuticals as their comparator comes off patent to reflect the lower price of the comparator as well as any new clinical and economic data.

    Read more →

 

Skip to toolbar